Vermillion, Inc. (NASDAQ:VRML) rose 10.1% on Thursday . The stock traded as high as $0.98 and last traded at $0.98, approximately 603,429 shares changed hands during trading. An increase of 268% from the average daily volume of 164,173 shares. The stock had previously closed at $0.89.
Separately, ValuEngine raised shares of Vermillion from a “hold” rating to a “buy” rating in a research note on Wednesday, May 15th.
The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 0.34. The firm’s 50 day moving average is $1.01.
In other Vermillion news, insider Valerie Barber Palmieri acquired 37,500 shares of Vermillion stock in a transaction on Friday, June 28th. The shares were purchased at an average cost of $0.80 per share, with a total value of $30,000.00. Following the completion of the purchase, the insider now owns 215,563 shares in the company, valued at $172,450.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Jack W. Schuler acquired 5,000,000 shares of Vermillion stock in a transaction on Friday, June 28th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $4,000,000.00. The disclosure for this purchase can be found here. Insiders have bought 5,042,500 shares of company stock worth $4,036,300 over the last three months. 4.40% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the business. Birchview Capital LP boosted its stake in Vermillion by 0.4% in the first quarter. Birchview Capital LP now owns 2,121,933 shares of the company’s stock valued at $2,440,000 after acquiring an additional 8,000 shares during the last quarter. Magnus Financial Group LLC bought a new position in Vermillion in the first quarter valued at approximately $35,000. Finally, B. Riley Wealth Management Inc. boosted its stake in Vermillion by 38.4% in the fourth quarter. B. Riley Wealth Management Inc. now owns 182,245 shares of the company’s stock valued at $55,000 after acquiring an additional 50,545 shares during the last quarter. 20.45% of the stock is currently owned by hedge funds and other institutional investors.
About Vermillion (NASDAQ:VRML)
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Read More: Understanding Options Trading
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.